Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, and SIRION Biotech GmbH announced the entry into a license agreement, pursuant to which Orchard has licensed SIRION’s LentiBOOST technology to enhance manufacturing efficiency for certain of Orchard’s ex vivo …

As quoted in the press release:

“At Orchard Therapeutics, we are establishing manufacturing capabilities to deliver potentially transformative gene therapy products to rare disease patients around the globe. Optimization of lentiviral transduction through a technology such as LentiBOOST™, along with the build-out of our recently announced manufacturing facility, are representative of our continued efforts to increase efficiencies and further streamline our approach to manufacturing gene therapy candidates,” said Stewart Craig, Ph.D., chief manufacturing officer of Orchard. “Current studies using LentiBOOST™ in our laboratories have resulted in encouraging data, and we look forward to examining the impact on our portfolio of gene therapy product candidates.”
Under the terms of the agreement, SIRION will provide Orchard with a license to its proprietary lentiviral transduction enhancer LentiBOOST™ for development and commercialization activities for select Orchard programs. SIRION will be entitled to upfront and milestone payments and is eligible to receive royalties on net sales of future products that utilize the LentiBOOST™ technology.

Click here to read the full press release.